Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis
Abstract
:1. Introduction
2. Methods
2.1. Study Design and Population
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ratjen, F.; Doring, G. Cystic fibrosis. Lancet 2003, 361, 681–689. [Google Scholar] [CrossRef]
- Rey, M.M.; Bonk, M.P.; Hadjiliadis, D. Cystic Fibrosis: Emerging Understanding and Therapies. Annu. Rev. Med. 2019, 70, 197–210. [Google Scholar] [CrossRef]
- Ramsey, B.W.; Davies, J.; McElvaney, N.G.; Tullis, E.; Bell, S.C.; Dřevínek, P.; Griese, M.; McKone, E.F.; Wainwright, C.E.; Konstan, M.W.; et al. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 2011, 365, 1663–1672. [Google Scholar] [CrossRef]
- Waters, V.J.; Kidd, T.J.; Canton, R.; Ekkelenkamp, M.B.; Johansen, H.K.; LiPuma, J.J.; Bell, S.C.; Elborn, J.S.; Flume, P.A.; VanDevanter, D.R.; et al. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clin. Infect. Dis. 2019, 69, 1812–1816. [Google Scholar] [CrossRef]
- Kidd, T.J.; Canton, R.; Ekkelenkamp, M.; Johansen, H.K.; Gilligan, P.; LiPuma, J.J.; Bell, S.C.; Elborn, J.S.; Flume, P.A.; VanDevanter, D.R.; et al. Defining antimicrobial resistance in cystic fibrosis. J. Cyst. Fibros. 2018, 17, 696–704. [Google Scholar] [CrossRef]
- Flume, P.A.; Waters, V.J.; Bell, S.C.; VanDevanter, D.R.; Elborn, J.S. Antimicrobial resistance in cystic fibrosis: Does it matter? J. Cyst. Fibros. 2018, 17, 687–689. [Google Scholar] [CrossRef]
- Goss, H.; Burns, J.L. Exacerbations in cystic fibrosis: Epidemiology and pathogenesis. Thorax 2007, 62, 360–367. [Google Scholar] [CrossRef]
- Somayaji, R.; Parkins, M.D.; Shah, A.; Martiniano, S.L.; Tunney, M.M.; Kahle, J.S.; Waters, V.J.; Elborn, J.S.; Bell, S.C.; Flume, P.A.; et al. Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. J. Cystt. Fibros. 2019, 18, 236–243. [Google Scholar] [CrossRef]
- Lambiase, A.; Catania, M.R.; del Pezzo, M.; Rossano, F.; Terlizzi, V.; Sepe, A.; Raia, V. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 2011, 30, 973–980. [Google Scholar] [CrossRef]
- Raso, T.; Bianco, O.; Grosso, B.; Zucca, M.; Savoia, D. Achromobacter xylosoxidans respiratory tract infections in cystic fibrosis patients. APMIS 2008, 116, 837–841. [Google Scholar] [CrossRef]
- Spicuzza, L.; Sciuto, C.; Vitaliti, G.; Di Dio, G.; Leonardi, S.; La Rosa, M. Emerging pathogens in cystic fibrosis: Ten years of follow-up in a cohort of patients. Eur. J. Clin. Microbiol. Infect. Dis. 2009, 28, 191–195. [Google Scholar] [CrossRef]
- De Baets, F.; Schelstraete, P.; Van Daele, S.; Haerynck, F.; Vaneechoutte, M. Achromobacter xylosoxidans in cystic fibrosis: Prevalence and clinical relevance. J. Cyst. Fibros. 2007, 6, 75–78. [Google Scholar] [CrossRef]
- Ballestero, S.; Virseda, I.; Escobar, H.; Suarez, L.; Baquero, F. Stenotrophomonas maltophilia in cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 1995, 14, 728–729. [Google Scholar] [CrossRef]
- Graff, G.R.; Burns, J.L. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002, 121, 1754–1760. [Google Scholar] [CrossRef]
- Stanojevic, S.; Ratjen, F.; Stephens, D.; Lu, A.; Yau, Y.; Tullis, E.; Waters, V. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J. Cyst. Fibros. 2013, 12, 575–583. [Google Scholar] [CrossRef]
- Ronne Hansen, C.; Pressler, T.; Hoiby, N.; Gormsen, M. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. J. Cyst. Fibros. 2006, 5, 245–251. [Google Scholar] [CrossRef]
- Cystic Fibrosis Trust. Antibiotic Treatment for Cystic Fibrosis; Cystic Fibrosis Trust: Bromley, UK, 2009; pp. 1–102. [Google Scholar]
- Amin, R.; Waters, V. Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis. Cochrane Database Syst. Rev. 2014, 4, CD009249. [Google Scholar]
- Psoter, K.J.; De Roos, A.J.; Wakefield, J.; Mayer, J.D.; Rosenfeld, M. Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis. BMC Infect. Dis. 2017, 17, 411–416. [Google Scholar] [CrossRef]
- Harness-Brumley, C.L.; Elliott, A.C.; Rosenbluth, D.B.; Raghavan, D.; Jain, R. Gender differences in outcomes of patients with cystic fibrosis. J. Women’s Health 2014, 23, 1012–1020. [Google Scholar] [CrossRef]
- Beauruelle, C.; Guilloux, C.A.; Lamoureux, C.; Héry-Arnaud, G. The human microbiome, an emerging key-player in the sex gap in respiratory diseases. Front. Med. 2021, 8, 600879. [Google Scholar] [CrossRef]
- Heirali, A.A.; Workentine, M.L.; Acosta, N.; Poonja, A.; Storey, D.G.; Somayaji, R.; Rabin, H.R.; Whelan, F.J.; Surette, M.G.; Parkins, M.D. The effects of inhaled aztreonam on the cystic fibrosis lung microbiome. Microbiome 2017, 5, 51. [Google Scholar] [CrossRef] [Green Version]
- Chotirmall, S.H.; Smith, S.G.; Gunaratnam, C.; Cosgrove, S.; Dimitrov, B.D.; O’Neill, S.J.; Harvey, B.J.; Greene, C.M.; McElvaney, N.G. Effect of estrogen on Pseudomonas mucoidy and exacerbations in Cystic Fibrosis. N. Eng. J. Med. 2012, 366, 1978–1986. [Google Scholar] [CrossRef]
- Tyrrell, J.; Harvey, B.J. Sexual dimorphism in the microbiology of the CF “Gender Gap”: Estrogen modulation of Pseudomonas aeruginosa virulence. Steroids 2020, 156, 108575. [Google Scholar] [CrossRef]
- Dalbøge, C.; Hansen, C.; Pressler, T.; Høiby, N.; Johansen, H. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. J. Cyst. Fibros. 2011, 10, 318–325. [Google Scholar] [CrossRef]
- Berdah, L.; Taytard, J.; Leyronnas, S.; Clement, A.; Boelle, P.-Y.; Corvol, H. Stenotrophomonas maltophilia: A marker of lung disease severity. Pediatr. Pulmonol. 2018, 53, 426–430. [Google Scholar] [CrossRef]
- Goss, C.H.; Mayer-Hamblett, N.; Aitken, M.L.; Rubenfeld, G.D.; Ramsey, B.W. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59, 955–959. [Google Scholar] [CrossRef]
- Goss, C.H.; Otto, K.; Aitken, M.L.; Rubenfeld, G.D. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2002, 166, 356–361. [Google Scholar] [CrossRef]
- Waters, V.; Yau, Y.; Prasad, S.; Lu, A.; Atenafu, E.; Crandall, I.; Tom, S.; Tullis, E.; Ratjen, F. Stenotrophomonas maltophilia in cystic fibrosis: Serologic response and effect on lung disease. Am. J. Respir. Crit. Care Med. 2011, 183, 635–640. [Google Scholar] [CrossRef]
- Waters, V.; Atenafu, E.G.; Lu, A.; Yau, Y.; Tullis, E.; Ratjen, F. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J. Cyst. Fibros. 2013, 12, 482–486. [Google Scholar] [CrossRef]
- Recio, R.; Brañas, P.; Martínez, M.T.; Chaves, F.; Orellana, M.A. Effect of respiratory Achromobacter spp. infection on pulmonary function in patients with cystic fibrosis. J. Med. Microbiol. 2018, 67, 952–956. [Google Scholar] [CrossRef]
- Tetart, M.; Wallet, F.; Kyheng, M.; Leroy, S.; Perez, T.; Le Rouzic, O.; Wallaert, B.; Prevotat, A. Impact of Achromobacter xylosoxidans isolation on the respiratory function of adult patients with cystic fibrosis. ERJ Open Res. 2019, 5, 00051–02019. [Google Scholar] [CrossRef] [Green Version]
- Firmida, M.; Pereira, R.; Silva, E.; Marques, E.; Lopes, A. Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis. Braz. J. Med. Biol. Res. 2016, 49, e5097. [Google Scholar] [CrossRef] [Green Version]
Patients Colonized with MDR Bacteria (n = 7) | Matched Controls (n = 14) | |
---|---|---|
Age (years) | 14.2 ± 1.8 | 14.3 ± 3.9 |
Genotype (F/F, n) | 2/7 | 2/14 |
BMI (kg/m2) | 16.9 ± 1.6 | 19.9 ± 3.4 * |
FEV1 pp % | 76.5 ± 27.0 | 88.7± 21.3 |
FVC pp | 88.1 ± 26.2 | 92.8 ± 14.7 |
FEV1/FVC | 75.7 ± 9.6 | 82.6 ± 10.1 ** |
Pex | 2 ± 1.6 | 0.3 ± 0.7 ** |
Patients Colonized with MDR Bacteria (n = 7) | Matched Controls (n = 14) | |
---|---|---|
Age (years) | 10.3 ± 2.2 | 10.6 ± 3.9 |
BMI (kg/m2) | 15.6 ± 1.9 | 19.2 ± 4.5 * |
FEV1 pp % | 87.6 ± 15.5 | 93.2 ± 12.8 |
FVC pp % | 101.0 ± 11.4 | 96.2 ± 13.3 |
FEV1/FVC % | 75.8 ± 9.4 | 87.0 ± 5.2 ** |
Pex | 5 ± 2.5 | 1.7 ± 2.3 * |
Patients Colonized with MDR Bacteria (n = 7) | Matched Controls (n = 14) | |
---|---|---|
Age (years) | 12.1 ± 1.4 | 11.9 ± 4.0 |
BMI (kg/m2) | 16.3 ± 2.5 | 18.6 ± 2.3 ** |
FEV1 pp % | 85.4 ± 14.6 | 88 ± 13.2 |
FVC pp % | 95.0 ± 13.4 | 90.3 ± 11.3 |
FEV1/FVC % | 77.7 ± 10.0 | 95.8 ± 7.8 ** |
Pex | 3.5 ± 3.2 | 1 ± 1.5 * |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Fainardi, V.; Neglia, C.; Muscarà, M.; Spaggiari, C.; Tornesello, M.; Grandinetti, R.; Argentiero, A.; Calderaro, A.; Esposito, S.; Pisi, G. Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis. Children 2022, 9, 1330. https://doi.org/10.3390/children9091330
Fainardi V, Neglia C, Muscarà M, Spaggiari C, Tornesello M, Grandinetti R, Argentiero A, Calderaro A, Esposito S, Pisi G. Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis. Children. 2022; 9(9):1330. https://doi.org/10.3390/children9091330
Chicago/Turabian StyleFainardi, Valentina, Cosimo Neglia, Maria Muscarà, Cinzia Spaggiari, Marco Tornesello, Roberto Grandinetti, Alberto Argentiero, Adriana Calderaro, Susanna Esposito, and Giovanna Pisi. 2022. "Multidrug-Resistant Bacteria in Children and Adolescents with Cystic Fibrosis" Children 9, no. 9: 1330. https://doi.org/10.3390/children9091330